Tscan Therapeutics Common Stock

Tscan Therapeutics (TCRX) currently reports a common stock of $6K as of March 2026. That compares with $6K in the prior-year period — up 0.0% year over year. Use the charts on this page to explore Tscan Therapeutics's common stock history and peer comparisons.

Tscan Therapeutics's common stock was unchanged from $6K to $6K — essentially flat versus a year earlier (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Tscan Therapeutics reported $6K in common stock as of March 2026. That compares with $6K in the prior-year period — up 0.0% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current common stock of $6K, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Tscan Therapeutics, and consider following TCRX for alerts when major investors trade the stock.

Tscan Therapeutics is classified in the Healthcare sector. On common stock, it currently shows $6K. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing TCRX with unrelated industries.